Magenta CEO exits, 84% of staff let go as shuttering looms
After a patient death, Magenta Therapeutics scrapped its stem cell transplant drug and went searching for alternatives last week. As it seeks an exit …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
